

ACTIVE LEARNING TEMPLATE: Medication

STUDENT NAME Divia Creamer

MEDICATION Influenza virus vaccine (inactivated) (Fluad, Flouxix) REVIEW MODULE CHAPTER _____

CATEGORY CLASS vaccine, inactivated (viral)

PURPOSE OF MEDICATION

Expected Pharmacological Action

Active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine

Therapeutic Use

Influenza disease prevention

Complications

Local: bruising, erythema, induration, pruritis, pain, swelling, and tenderness

GI: anorexia

Nervous: HA, dizziness, fatigue/malaise, irritability

Misc.: fever, myalgia, chest tightness

Medication Administration

IM: 0.5 mL / dose / season

- consider high dose immunization for elder / high risk patients.

Contraindications/Precautions

Acute illness: consider delaying immunization

Bleeding disorders / anticoagulant therapy

Hx. febrile seizures

Pt's with altered immunocompetence

- allergy to chicken egg protein

Nursing Interventions

- monitor pt ≥ 15 min after administration

- Assess allergies and perform med.

reconciliation prior to admin.

- Education (S/E, benefits)
- Recommend high dose for older populations.

Interactions

Acetaminophen

Corticosteroids

Immuno suppressants

Anti-CD20 B-cell depleting therapies

} diminished therapeutic effect of vaccine

Client Education

- Provide VIS
- Advise seasonal vaccination
- Hand hygiene
- move arm frequently to prevent soreness.
- report discussed unusual side effects
- Delay vaccination if currently sick

Evaluation of Medication Effectiveness

- reduced transmission of virus
- reduced prevalence of virus
- reducing severity of symptoms and preventing hospitalization

ACTIVE LEARNING TEMPLATE: Medication

STUDENT NAME Olivia Creamer
MEDICATION Pneumococcal Polysaccharide Vaccine (23 Valent) REVIEW MODULE CHAPTER _____
CATEGORY CLASS Vaccine, inactivated (bacterial)

PURPOSE OF MEDICATION

Expected Pharmacological Action

Active immunization promoting the production of antibodies against the pneumococcal disease caused by the 23 serotypes.

Therapeutic Use

Prevention and reduction in the severity of symptoms of the pneumococcal disease

Complications

Local: erythema, induration, soreness, and swelling at injection site
CNS: HA, fatigue
musculoskeletal: asthenia, myalgia

Medication Administration

IM / Subq: 0.5 mL IM or subq using pre-filled syringe

Contraindications/Precautions

Bleeding disorders / bleeding / hematoma may ^{anticoagulant therapy result}
Acute illness: consider delay in admin
Cardiac disease hx: systemic reaction can pose risk
CSF leaks: therapeutic effect may be diminished

Nursing Interventions

- Monitor the client >15 mins after admin
- Assess allergies
- provide V/S (education)
- provide ice to reduce localized swelling
- Discuss risks/benefits

Interactions

Acetaminophen: can diminish therapeutic effect
Immunosuppressants
Methotrexate
Corticosteroids; anti CD40 B-cell depleting therapies

Client Education

Keep arm/injection site mobile to prevent soreness
Additional vaccines may be necessary next season
This vaccine may not completely prevent developing this illness
• Advise effects / what to report.

Evaluation of Medication Effectiveness

- reduced prevalence of the pneumococcal disease
- Less severe symptoms if the disease is contracted → prevention of hospitalization